Moderna’s cancer vaccine pipeline centers on a personalized mRNA technology that turns each patient’s own tumor mutations into a custom-made treatment. The most advanced candidate, originally called mRNA-4157 (V940) and now known as intismeran autogene, has produced striking results in melanoma when paired with the checkpoint inhibitor pembrolizumab, cutting the risk of recurrence or death roughly in half compared to pembrolizumab alone. But the pipeline extends well beyond a single trial in a single cancer type, and the science behind it reveals both how far personalized cancer vaccines have come and how many hurdles remain before they reach widespread clinical use.
How the Personalized mRNA Vaccine Works
The core idea is deceptively simple. Cancer cells accumulate mutations, and some of those mutations produce altered proteins on the cell surface that the immune system can, in theory, recognize as foreign. These altered proteins are called neoantigens. Moderna’s approach starts with sequencing a patient’s tumor, identifying up to 34 of the most promising neoantigens, and then encoding all of them into a single strand of mRNA. That mRNA is wrapped in a lipid nanoparticle and injected into the patient’s muscle, where it instructs cells to produce those neoantigen fragments. Immune cells then learn to recognize and attack tumor cells carrying those same markers.
The vaccine triggers a coordinated immune attack involving multiple types of immune cells. Killer T cells (CD8+) directly destroy tumor cells displaying the neoantigens, while helper T cells (CD4+) amplify the response by supporting the killer cells and reshaping the environment around the tumor to make it less hospitable to cancer.1PubMed Central. Take Five : harmonization in personalized cancer vaccines for cancer immunotherapy The vaccine essentially trains both arms of the adaptive immune system to hunt the same target from different angles.
The Melanoma Trial That Put the Pipeline on the Map
The strongest clinical evidence for Moderna’s approach comes from the KEYNOTE-942 study, a randomized phase 2b trial in patients with high-risk melanoma that had been surgically removed. Patients received either intismeran autogene plus pembrolizumab or pembrolizumab alone. The initial readout showed that the combination group had longer recurrence-free survival, with an 18-month recurrence-free survival rate of 79% versus 62% for pembrolizumab alone.2PubMed. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
What made the data more convincing over time was that the benefit held up and even appeared to strengthen. At the three-year update, the combination maintained a 49% reduction in the risk of recurrence or death, with a 2.5-year recurrence-free survival rate of about 75% in the combination arm versus roughly 56% for pembrolizumab alone. The vaccine also showed a meaningful improvement in distant metastasis-free survival, meaning patients were less likely to develop cancer spread to other organs.3Journal of Clinical Oncology. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial By the five-year update, the safety profile remained manageable with no new safety signals emerging, which is reassuring for a treatment patients receive over many cycles.4PubMed. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study
A few things worth noting about these results. The trial was relatively small, with 107 patients in the combination arm and 50 in the control arm, and it was a phase 2b study rather than a definitive phase 3 confirmation. The initial hazard ratio for recurrence-free survival did not quite reach traditional statistical significance at the first readout. The ongoing phase 3 trial (called V940-001 or KEYNOTE-D18) in melanoma, as well as trials in non-small cell lung cancer and other solid tumors, will ultimately determine whether the treatment earns regulatory approval. Still, the consistency of the benefit across multiple time points has generated genuine excitement in the field.
Picking the Right Neoantigens
The effectiveness of a personalized cancer vaccine hinges entirely on choosing the right targets. Not every mutation in a tumor produces a neoantigen that the immune system can recognize, and not every recognizable neoantigen will provoke a strong enough immune response to matter clinically. The selection process involves sequencing the tumor, comparing it to the patient’s healthy tissue, identifying mutations, and then predicting which mutated protein fragments will bind tightly to the patient’s specific immune recognition molecules and provoke a T cell response.5PubMed Central. Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy
This is where artificial intelligence has become essential. The computational challenge is enormous: a single tumor can harbor thousands of mutations, but only a fraction produce neoantigens worth targeting. Machine learning models now evaluate multiple features of each candidate neoantigen, including physical properties like how water-soluble the peptide is and how long the fragment is, both of which turn out to be strong predictors of whether the immune system will actually respond.6PubMed Central. NeoTImmuML: a machine learning-based prediction model for human tumor neoantigen immunogenicity AI tools have matured rapidly in this space, now spanning the entire pipeline from finding mutations to predicting which peptide fragments will bind to immune molecules and ultimately trigger a T cell attack.7PubMed Central. Artificial intelligence in peptide cancer vaccine design: from neoantigen discovery to immunogenicity prediction
The accuracy of these predictions directly affects how well the vaccine works. If the algorithm selects neoantigens that do not actually provoke a strong immune response, the vaccine wastes some of its payload. Improvements in prediction models are one of the fastest-moving areas in cancer vaccine development, because better target selection can improve outcomes without changing anything about the vaccine’s physical formulation or delivery.
Expanding Beyond Melanoma
Melanoma is a logical starting point for a neoantigen vaccine because melanoma tumors tend to carry a high number of mutations, giving the algorithm more candidates to choose from. But Moderna’s ambitions are broader. The early KEYNOTE-603 trial tested mRNA-4157 as a single agent and in combination with pembrolizumab across multiple solid tumor types, with patients receiving up to nine cycles of the vaccine by intramuscular injection.8healthbook TIMES Oncology Hematology. mRNA Vaccines Against Infectious Diseases and Cancer – Section: CURRENT STATUS OF mRNA VACCINES FOR CANCER IMMUNOTHERAPY
Pancreatic cancer is one of the most challenging tumor types in oncology, and early signals there are particularly noteworthy. A pilot study combining a personalized cancer vaccine with checkpoint inhibitors in advanced pancreatic cancer found that the vaccine could provoke strong neoantigen-specific T cell responses. In two patients evaluated, the immune system responded to the vast majority of the targeted neoantigens, with one patient responding to all 20 encoded targets. These immune responses appeared as early as the third treatment cycle and persisted through the ninth.9Journal of Clinical Oncology. A pilot study of a personalized cancer vaccine in combination with immune checkpoint inhibitor in advanced pancreatic cancer Pancreatic tumors are notoriously resistant to immunotherapy, so even generating measurable immune responses is considered meaningful progress, though it remains early days.
Moderna has also explored a different strategy with mRNA-5671 (also called V941), an off-the-shelf vaccine that targets four common mutations in the KRAS gene. Unlike the personalized approach, this vaccine is not tailored to each patient’s tumor. Instead, it targets mutations shared across many patients’ cancers, particularly in pancreatic, colorectal, and lung cancers where KRAS mutations are common drivers. The trade-off is clear: an off-the-shelf product is far simpler to manufacture and distribute, but it may not match the precision of a fully personalized vaccine. This two-track strategy, personalized for some cancers and shared-antigen for others, reflects the reality that different tumor types may require different approaches.
The Checkpoint Inhibitor Partnership
A cancer vaccine alone faces a fundamental problem. Even if it successfully trains the immune system to recognize tumor cells, the tumor has ways to shut that immune response down. Many cancers deploy molecular “brakes” that prevent T cells from attacking. Checkpoint inhibitors like pembrolizumab work by releasing those brakes. Combining the two makes biological sense: the vaccine provides the targets, and the checkpoint inhibitor removes the barriers.
Research on combining cancer vaccines with checkpoint inhibitors has shown that the effect is genuinely synergistic, not merely additive. The combination boosts the generation, activation, and expansion of killer T cells while also increasing the production of proteins that inhibit tumor growth. The combined effect consistently outperforms either approach used alone.10PubMed. Combining anti-checkpoint immunotherapies and cancer vaccines as a novel strategy in oncological therapy: A review This is why virtually every trial in Moderna’s pipeline pairs the mRNA vaccine with pembrolizumab or another checkpoint inhibitor rather than testing it as a standalone treatment.
Researchers are also investigating combinations with newer checkpoint agents beyond the standard PD-1 inhibitors. Antibodies targeting CD40, OX40, and other immune checkpoints have shown promise alongside cancer vaccines in both laboratory models and early human studies, suggesting that the next generation of combination strategies could involve multiple checkpoint inhibitors layered on top of the vaccine.
Optimizing the Delivery Vehicle
The lipid nanoparticle that carries the mRNA into cells is not just packaging; it is a critical component that affects where the vaccine ends up and how well it works. The same basic technology underlies the COVID-19 mRNA vaccines, but cancer vaccines have different requirements. For a cancer vaccine, you ideally want the mRNA to reach immune cells in the lymph nodes and spleen, where the immune response is organized, rather than just muscle cells at the injection site.
Recent work has focused on engineering lipid nanoparticles that naturally accumulate in lymph nodes without needing any special targeting molecules attached to their surface. One experimental formulation showed substantially better expression in lymph nodes compared to the lipid nanoparticle used in Pfizer’s COVID-19 vaccine, and it generated a stronger killer T cell response in animal models.11PubMed Central. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response Particle size also matters more than researchers initially appreciated. Studies optimizing lipid nanoparticle formulations for reaching immune cells in the spleen have found that a specific size range, roughly 200 to 500 nanometers, works best for uptake by the dendritic cells that kick off the immune response. The best-performing formulation in one study outperformed two clinically relevant comparison formulations in both immune cell activation and antitumor effects.12PubMed Central. mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy
These delivery improvements are happening in parallel with the clinical trials and could be incorporated into future formulations. A better delivery vehicle does not change which neoantigens the vaccine targets, but it can make the same payload more effective by ensuring it reaches the right immune cells.
Why mRNA May Have an Edge Over Other Platforms
Moderna is not the only company developing neoantigen cancer vaccines. Competitors use synthetic peptides, viral vectors, and dendritic cell-based approaches. Each platform has strengths, but mRNA has a few practical and biological advantages that explain why it has attracted so much investment.
In a head-to-head comparison in a mouse lung cancer model, an mRNA-based neoantigen vaccine significantly outperformed a synthetic peptide-based version in preventing tumor growth, especially in animals with lower initial tumor burden.13PubMed Central. Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model This is one preclinical study in mice, so it does not prove the same advantage holds in humans, but it aligns with the theoretical rationale: mRNA vaccines can encode multiple full-length neoantigens in a single construct, and the mRNA itself acts as an immune stimulant that helps activate the innate immune system alongside the adaptive response.
Manufacturing speed is another differentiator. Peptide-based personalized vaccines typically require around seven to eight weeks from tumor sequencing to finished product. Viral vector platforms take about eight weeks as well.14PubMed Central. Artificial intelligence for translational personalized neoantigen cancer vaccine development mRNA vaccines can theoretically be produced faster because the manufacturing process is the same regardless of which neoantigens are encoded: you change the digital sequence, but the physical production steps remain identical. For a patient with aggressive cancer, weeks matter.
Manufacturing and Regulatory Challenges
Making a unique vaccine for each patient creates logistical challenges that traditional pharmaceuticals never face. Every batch is a batch of one. There is no stockpile, no generic version, and no way to run a single manufacturing campaign for thousands of doses. The process requires tumor sequencing, bioinformatics analysis, mRNA synthesis, lipid nanoparticle encapsulation, quality testing, and shipping, all before the patient’s cancer progresses. Scaling this to thousands or millions of patients worldwide is a fundamentally different problem from scaling a COVID-19 vaccine.
The regulatory framework adds another layer of complexity. Existing rules for drug manufacturing were designed for standardized products where thousands of identical units come off a single production line. A personalized vaccine that changes for every patient does not fit neatly into that model. Current regulatory mechanisms for post-approval manufacturing changes can handle minor adjustments, but they become impractical when the manufacturing process itself evolves rapidly with new sequencing technologies, better bioinformatics tools, and improved nanoparticle formulations.15Cell and Gene Therapy Insights. A need for a novel regulatory framework for individualized neoantigen-specific therapies Regulators in both the United States and Europe are actively working on frameworks that can accommodate this kind of product, but the path is still being charted. The FDA’s breakthrough therapy designation for intismeran autogene in melanoma signals willingness to expedite the process, though formal approval requires phase 3 data.
What Could Limit the Approach
Despite the promising data, personalized cancer vaccines face real biological obstacles. The tumor microenvironment is one of the biggest. Tumors do not just grow passively; they actively build a local environment that suppresses immune responses. Immunosuppressive cells accumulate around the tumor, signaling molecules that dampen T cell activity flood the area, and some tumor cells evolve to hide their neoantigens entirely. Over a century of cancer vaccine research has shown that the tumor microenvironment is one of the primary reasons vaccines that generate strong immune responses in the bloodstream sometimes fail to shrink actual tumors.16PubMed Central. Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review
Tumor escape is another concern. Cancer is genetically unstable, and tumors can shed the mutations targeted by the vaccine while continuing to grow using other mutations. If a vaccine targets 34 neoantigens and the tumor loses even a few of them, some cancer cells may evade the immune attack entirely. This is one reason the personalized approach encodes many neoantigens rather than just one or two: targeting more mutations makes it harder for the tumor to escape them all.
Cancer cell resistance to immune killing itself has also been identified as a significant hurdle for therapeutic vaccines, separate from the microenvironment issue.17PubMed. Cancer vaccines: An unkept promise? Some tumor cells downregulate the molecular machinery that presents neoantigens on their surface, becoming essentially invisible to T cells even when those T cells are present and activated. Combining vaccines with agents that force tumors to maintain antigen presentation is an active area of research.
The Question of “Cold” Tumors
Not all cancers are equally suited to a personalized neoantigen approach. Tumors with high mutation rates, like melanoma and certain lung cancers, produce many neoantigens and tend to have more immune cells already infiltrating the tumor. These are sometimes called immunologically “hot” tumors, and they respond better to immunotherapy in general. “Cold” tumors, by contrast, have fewer mutations, less immune infiltration, and are much harder targets. Cancers like certain breast cancers, prostate cancer, and glioblastoma often fall into this category.
For cold tumors, a personalized neoantigen vaccine faces a double challenge: fewer good targets to choose from, and an immune system that has not been naturally primed against the tumor at all. This is where the off-the-shelf approach targeting shared mutations like KRAS may prove more practical. KRAS mutations are found across multiple cancer types and are potent drivers of tumor growth, making them attractive vaccine targets even in tumors with relatively few total mutations. The broader question facing the field is whether mRNA cancer vaccines can eventually reach into these harder-to-treat tumor types, or whether their greatest impact will remain concentrated in mutation-rich cancers where the immune system already has a foothold.